David Somerman, DO
Nephrology · Lancaster, PANPI 1255586178
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $6,937 of the $8,043 with a category attached, or 86.2%. AstraZeneca accounts for 90.0% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $4,808 and has fallen 90.5% since, to $455 in 2025. Among nephrology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 38 payments — averaging $211.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$7K
- Amgen$276
- Vifor Pharma, Inc.$125
- Bayer$72
- Travere Therapeutics, Inc.$66
- Novartis$54
- plus $216 from 8 others
Across 24 payments — averaging $4431.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$106K
What the payments were for
- Speaking & faculty fees$6,93786%
- Food & beverage$1,10514%
- Education$20%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 10 | $7,235 |
| Amgen | 7 | $276 |
| Vifor Pharma, Inc. | 1 | $125 |
| Bayer | 3 | $72 |
| Travere Therapeutics, Inc. | 5 | $66 |
| Novartis | 2 | $54 |
| Akebia Therapeutics Inc | 3 | $51 |
| Otsuka America Pharmaceutical, Inc. | 1 | $30 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $27 |
| Mallinckrodt Hospital Products Inc. | 1 | $26 |
| OPKO Pharmaceuticals, LLC | 1 | $24 |
| Fresenius USA Marketing, Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $20 |
| Johnson & Johnson | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,043 in reported general payments places this provider in the 90th percentile of 586 nephrology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 81 | $91,685 |
| FarxigaDapagliflozin Propanediol | 63 | $60,375 |
| Sevelamer Carbonate | 22 | $9,248 |
| Cinacalcet Hcl | 18 | $3,961 |
| Nifedipine ErNifedipine | 113 | $3,386 |
| Torsemide | 155 | $2,923 |
| Carvedilol | 233 | $2,707 |
| Losartan Potassium | 328 | $2,690 |
| Amlodipine Besylate | 423 | $2,426 |
| Lisinopril | 397 | $2,068 |
| Valsartan | 72 | $2,053 |
| Doxazosin Mesylate | 118 | $2,026 |
| Nebivolol Hcl | 30 | $1,961 |
| Bumetanide | 46 | $1,748 |
| Calcium Acetate | 22 | $1,685 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $20 | $91,68581 claims |
| AstraZenecaFarxiga | $7,235 | $60,37563 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 586 nephrology providers in Pennsylvania.
Other nephrology in Lancaster
- Nelson KopytAllentown$949K
- Christopher GislerPittsburgh$757K
- Rakesh GulatiPhiladelphia$657K
- Raymond TownsendPhiladelphia$357K
- Prince AnandDanville$331K
- Ellie KelepourisPhiladelphia$287K
- Jonathan DiamondHarrisburg$249K
- Abdallahsassine GearaPhiladelphia$225K
- Khaled NasharPittsburgh$198K
- Katalin SusztakPhiladelphia$192K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.